BURTON, J. H.; MITCHELL, L.; DOW, S. W. et al. Low­dose cyclophosphamide selectively decreases regulatory T cells and

inhibits angiogenesis in dogs with soft tissue sarcoma. J. Vet. Inter. Med., v. 25, n. 4, p. 920­926, 2011.

MARCHETTI, V.; GIORGI M.; FIORAVANTI, A. et al. First­line metronomic chemotherapy in a metastatic model of spontaneous

canine tumours: a pilot study. Invest. New Drugs, v. 30, n. 4, p. 1725­1730, 2012.

LEO, C.; STELL, A.; BORREGO, J. et al. Evaluation of low­dose metronomic (LDM) cyclophosphamide toxicity in cats with

malignant neoplasia. J Fel. Med. Surg., p. 671­678, 2014.

SHAND, F. L. The immunopharmacology of cyclophosphamide. Internat. J. Immunopharmacol., v. 1, n. 3, p. 165­171, 1979.

WHITLEY, N. T.; DAY, M. J. Immunomodulatory drugs and their application to the management of canine immune­mediated

disease. J. Small Anim. Pract., v. 52, n. 2, p. 70­85, 2011.

MUNDY, P.; DA SILVA, E. C.; LEDBETTER, E. C. Effects of cyclophosphamide myelosuppression in adult dogs with latent

canine herpesvirus­1 infection. Vet. Microbiol., v. 159, n. 1, p. 230­235, 2012.

WARRY, E.; HANSEN, R. J.; GUSTAFSON, D. L. et al. Pharmacokinetics of cyclophosphamide after oral and intravenous

administration to dogs with lymphoma. J. Vet. Intern. Med., v. 25, n. 4, p. 903­908, 2011.

RASSNICK, K. M.; FRIMBERGUER, A. E.; WOOD, C. A. et al. Evaluation of ifosfamide for treatment of various canine

neoplasms. J. Vet. Intern. Med., v. 14, n. 3, p. 271­276, 2000.

RASSNICK, K. M.; RODRIGUEZ, C. O.; KHANNA, C. et al. Results of a phase II clinical trial on the use of ifosfamide for

treatment of cats with vaccine­associated sarcomas. Am. J. Vet. Res., v. 67, n. 3, p. 517­523, 2006.

STEIN, T.; PELLIN, M.; STEINBERG, H. et al. Treatment of feline gastrintestinal small­cell lymphoma with chlorambucil and

glucocorticoids. J. Am. Anim. Hosp. Assoc., v. 46, n. 6, p. 413­417, 2010.

SCHREMPP, D. R.; CHILDRESS, M. O.; STEWART, J. C. et al. Metronomic administration of chlorambucil for treatment of dogs

with urinary bladder transitional cell carcinoma. J. Am. Vet. Med. Assoc., v. 242, n. 11, p. 1534­1538, 2013.

BENITAH, N.; LORIMIER, L. P.; GASPAR, M. et al. Chlorambucil­induced myoclonus in a cat with lymphoma. J. Am. Anim.

Hosp. Assoc., v. 39, n. 3, p. 283­287, 2003.

GIULIANO, A. Suspected chlorambucil­related neurotoxicity with seizures in a dog. J. Small Anim. Pract., v. 54, n. 8, p. 437­437,

2013.

EMMS, S. G. Anal sac tumours of the dog and their response to cytoreductive surgery and chemotherapy. Austral. Vet. J., v. 83, n. 6,

p. 340­343, 2005.

VAN MEERVENNE, S.; VERHOEVEN, P. S.; DE VOS, J. et al. Comparison between symptomatic treatment and lomustine

supplementation in 71 dogs with intracranial, space­occupying lesions. Vet. Comp. Oncol., v. 12, n. 1, p. 67­77, 2014.

SABA, C. F.; VAIL, D. M.; THAMM, D. H. Phase II clinical evaluation of lomustine chemotherapy for feline vaccine associated

sarcoma. Vet. Comp. Oncol., v. 10, n. 4, p. 283­291, 2012.

SKORUPSKI, K.; HAMMOND, G. M.; IRISH, A. M. A. et al. Prospective randomized clinical trial assessing the efficacy of

denamarin for prevention of CCNU induced hepatopathy in tumor bearing dogs. J. Vet. Intern. Med., v. 25, n. 4, p. 838­845, 2011.

DERVISIS, N. G.; DOMINGUEZ, P. A.; NEWMAN, R. G. et al. Treatment with DAV for advanced­stage hemangiossarcoma in

dogs. J. Am. Anim. Hosp. Assoc., v. 47, n. 3, p. 170­178, 2011.

FINOTELLO, R.; STEFANELLO, D.; BETTINI, G. et al. Preliminary study on a combined doxorubicin­dacarbazine

chemotherapeutic protocol for the adjuvant treatment of canine hemangiosarcoma. In: World Veterinary Cancer Congress, 2012.

VENABLE, R. O.; WORLEY, D. R.; GUSTAFSON, D. L. et al. Effects of intratumoral administration of a hyaluronan­cisplatina

nanoconjugate to five dogs with soft tissue sarcomas. Am. J. Vet. Res., v. 73, n. 12, p. 1969­1976, 2012.

FIDEL, J.; LYONS, J.; TRIPP, C. et al. Treatment of oral squamous cell carcinoma with accelerated radiation therapy and

concomitant carboplatina in cats. J. Vet. Intern. Med., v. 25, n. 3, p. 504­510, 2011.

MENAUT, P.; LANDART, J.; BEHR, S. et al. Treatment of 11 dogs with meningoencephalomyelitis of unknown origin with a

combination of prednisolone and cytosine arabinoside. Vet. Record J. Brit. Vet. Assoc., v. 162, n. 8, 2008.

FORMARIZ, T. P.; CHIAVACCI, L. A.; SARMENTO, V. H. et al. Relationship between structural features and in vitro release of

doxorubicin from biocompatible anionic microemulsion. Colloid. Surf. B. Biointer. Faces, v. 60, p. 28­35, 2007.

ASSUMPÇÃO, J. U. C. V.; CAMPOS, M. L.; NOGUEIRA FILHO, M. A. et al. Biocompatible microemulsion modifies the

pharmacokinetic profile and cardiotoxicity of doxorubicin. J. Pharm. Scienc., v. 102, n. 1, 2013.

Bibliografia

ALLEGRA, C. J.; FINE, R. L.; CHABNER, B. A. The effect of methotrexate on intracellular folate pools in human MCF­7 breast cancer

cells. Evidence for direct inhibition of purine synthesis. J. Biol. Chem., v. 261, n. 14, p. 6478­6485, 1986.

ALLEGRA, C. J.; GREM, J. L. Antimetabolites. In: DEVITA JR., V. T.; HELLMAN, S.; ROSENBERG, S. A. Cancer principles and

practice of oncology. 5. ed. Philadelphia: Lippincott­Raven, v. 1, p. 432­452, 1997.

ALLEN, D. G.; PRINGLE, J. K.; SMITH, D. A. Handbook of Veterinary Drugs. 2. ed. Philadelphia: Lippincott/Raven, 1998.

AMBER, E.; HENDERSON, R. A.; ADEYANJU, J. B. et al. Single drug chemotherapy of canine transmissible venereal tumour with

cyclophosphamide, metrotrexate, or vincristine. J. Vet. Intern. Med., v. 4, n. 3, p. 144­147, 1990.

ANDRADE, C. M.; FERNANDES, H. J.; CAVALHEIRO, R. C. R. et al. O tratamento clínico do câncer. In: BARACAT, F. F.;

FERNANDES JR., H. J.; SILVA, M. J. Cancerologia Atual. São Paulo: Roca, p. 104­116, 2000.

ANDRADE, S. F.; OLIVEIRA, C. M. N. L.; COTTA­LUIZARI, F. et al. Normas de segurança para o uso da vincristina no tratamento de

tumor venéreo transmissível em cães. Clín. Vet., v. 18, p. 32­33, 1999.

ANELLI, T. F. M. Quimioterapia. In: BRENTANI, M. M. et al. Bases da Oncologia. São Paulo: Lemar, 1998.

ARRINGTON, K. A.; LEGENDRE, A. M.; TABELING, G. S. et al. Comparison of body surface area­based and weight­based dosage

protocols for doxorubicin administration in dogs. Am. J. Vet. Res., v. 55, p. 1587, 1994.

AUDETTE, R. C.; CONNORS, T. A.; MANDEL, H. G. et al. Studies on the mechanism of action of the tumour inhibitory triazenes.

Bioch. Pharmacol., v. 22, n. 15, p. 1855­1864, 1973.

BAILEY, D. B.; RASSNICK, K. M. Effect of glomerular filtration rate on clearance and myelotoxicity of carboplatina in cats with

tumors. Am. J. Vet. Res. v. 65, p. 1502, 2004.

BAKER, E. S.; CONNOR, T. H. Monitoring occupational exposure to cancer chemotherapy drugs. Am. J. Health­System Pharmacol., v.

53, p. 2713­2723, 1996.

BALCH, C. M.; PELLIS, N. R.; MORTON, D. L. et al. Oncologia. In: SCHWARTZ, S. I.; SHIRES, G. T.; SPENCER, F. C. Princípios de

Cirurgia. 6. ed. México: McGraw­Hill, v. 1, p. 275­338, 1993.

BALDI, A.; COLLOCA, E.; SPUGNINI, E. P. Lomustine for the treatment of gastrintestinal mast cell tumour in a dog. J. Small Anim.

Pract., v. 47, n. 8, p. 465­467, 2006.

BATSCHINSKI, K.; DERVISIS, N. G.; KITCHELL, B. E. Evaluation of ifosfamide salvage therapy for metastatic canine osteosarcoma.

Vet. Comp. Oncol., v. 12, n. 4, p. 249­257.

BEGLEITER, A.; LAM, H. P.; GROVER, J. et al. Evidence for active transport of melphalan by two amino acid carriers in L5178Y

lymphoblasts in vitro. Cancer Res., v. 39, n. 2, p. 353­359, 1979.

BONASSA, E. M. A. Aspectos relativos à segurança do operador e do ambiente. In: Enfermagem em Quimioterapia. São Paulo: Atheneu,

p. 29­36, 1992.

BONNEY, P. T.; KNAPP, D. W. Chemotherapy safety: a guide for veterinary practitioners. Vet. Cancer Soc. News., v. 17, n. 2, p. 10­11,

1993.

BOYLE, D. M.; ENGELKING, C. Vesicant extravasation: myths and realities. Oncol. Nurs., v. 22, n. 1, p. 57­67, 1995.

BRABEC, V.; KASPARKOVA, J. Modifications of DNA by platinum complexes: relation to resistance of tumors to platinum antitumor

drugs. Drug Resist. Updates, v. 8, n. 3, p. 131­146, 2005.

BRASIL. MINISTÉRIO DA SAÚDE. INSTITUTO NACIONAL DO CÂNCER. Controle do câncer: uma proposta de integração ensinoserviço. 2. ed. Revista Atual. Rio de Janeiro: Pro­Onco, 1993.

BROCKLEY, L. K.; COOPER, M. A.; BENNETT, P. F. Malignant melanoma in 63 dogs (2001–2011): the effect of carboplatina

chemotherapy on survival. New Zealand Vet. J., v. 61, n. 1, p. 25­31, 2013.

BROWN, J. M.; WOUTERS, B. G. Apoptosis, p. 53, and tumor cell sensitivity to anticancer agents. Cancer Res., v. 59, p. 1391­1399,

1999.

BUDMAN, D. R. Vinorelbine (navelbiner): a third­generation vinca alkaloid. Cancer Invest., v. 15, n. 5, p. 475­490, 1997.

CALSOU, P.; SALLES, B. Role of DNA repair in the mechanisms of cell resistance to alkylating agents and cisplatina. Cancer

Chemother. Pharmacol., v. 32, n. 2, p. 85­89, 1993.

CAMPBELL, M. W.; HESS, P. R.; WILLIAMS, L. E. Chronic lymphocytic leukaemia in the cat: 18 cases (2000–2010). Vet. Comp.

Oncol., v. 11, n. 4, p. 256­264, 2013.

CARMAN, M. D.; SCHORNAGEL, J. H.; RIVEST, R. S. et al. Resistance to methotrexate due to gene amplification in a patient with

acute leukemia. J. Clin. Oncol., v. 2, n. 1, p. 16­20, 1984.

CARMIGNANI, S. S.; RAYMOND, G. G. Safe handling of cytotoxic drugs in the physician’s office: a procedure manual model. Oncology

Nursing. v. 24, p. 41­48, 1997.

CHABNER, B. A.; ALLEGRA, C. J.; CURT, G. A. et al. Antineoplastic agents. In: GOODMAN, A.; GILMANS, B. The

Pharmacological Basis of Therapeutics. 9. ed. New York: McGraw­Hill, p. 1259­1260, 1996.

CHABNER, B. A.; SPONZO, R.; HUBBARD, S. et al. High­dose intermittent intravenous infusion of procarbazine (NSC­77213). Cancer

Chemother. Reports, v. 57, n. 3, p. 361­363, 1972.

CHABNER, B. A: Clinical strategies for cancer treatment: the role of drugs. In: Chabner B. A, Collins J. M. Cancer Chemotherapy:

Principles and Practice, Philadelphia: JB Lippincott, 1990.

CHUN, R.; GARRET, L. D.; VAIL, D. M. Cancer chemotherapy. In: WITHROW, S. J.; MACEWEN, E. G. Withrow & MacEwen’s Small

Animal Clinical Oncology. St. Louis: Saunders Elsevier, p. 163­192, 2007.

CLEMENTS, D. N.; HOGAN, A. M.; CAVE, T. A. Treatment of a well differentiated pulmonary adenocarcinoma in a cat by

pneumonectomy and adjuvant mitoxantrone chemotherapy. J. Fel. Med. Surg., v. 6, n. 3, p. 199­205, 2004.

COLVIN, M.; BRUNDRETT, R. B.; COWENS, W. et al. A chemical basis for the antitumor activity of chloroethylnitrosoureas.

Biochem. Pharmacol., v. 25, n. 6, p. 695­699, 1976.

COUTO, C. G. Quimioterapia prática. In: NELSON, R. W.; COUTO, C. G. Fundamentos de Medicina Interna de Pequenos Animais. Rio

de Janeiro: Guanabara Koogan, p. 620­623, 1992.

CRAIG, M. Disease facts: pemphigus foliaceus in the dog and cat. Compan. Anim., v. 18, n. 8, p. 374­377, 2013.

DALECK, C. R.; DE NARDI, A. B.; RODASKI, S. Oncologia em cães e gatos, 1

a ed. São Paulo: Roca, 2009.

DEVITA JR., V. T. Principles of chemotherapy. In: DEVITA JR., V. T.; JELLMAN, S.; ROSENBEG, S. A. Cancer: Principles and

Practice of Oncology. 2. ed. Philadelphia: J. B. Lippincott, p. 257­285, 1995.

DICKINSON, K.; OGILVIE, G. K. Safe handling and administration of chemotherapeutic agents in veterinary medicine. In: KIRK, R. W.;

BONAGURA, J. D. Current veterinary therapy XII. Small Anima Practice. Philadelphia: WB Saunders, p. 475­478, 1995.

DIMSKI, D. S.; COOK JR., J. R. Carmustine­induced partial remission of an astrocytoma in a dog. J. Am. Anim. Hosp. Assoc., v. 26, p.

179­182, 1990.

DRABLOS, F.; FEYZI, E.; AAS, P. A. et al. Alkylation damage in DNA and RNA–repair mechanisms and medical significance. DNA

Repair, v. 3, n. 11, p. 1389­1407, 2004.

DUMONTET, C.; SIKIC, B. I. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and

cell death. J. Clin. Oncol., v. 17, n. 3, p. 1061­1061, 1999.

ELWOOD, C.; DEVAUCHELLE, P.; ELLIOT, J. et al. Emesis in dogs: a review. J. Small Anim. Pract., v. 51, n. 1, p. 4­22, 2010.

FAHEY, C. E.; MILNER, R. J.; BARABAS, K. et al. Evaluation of the University of Florida lomustine, vincristine, procarbazine, and

prednisone chemotherapy protocol for the treatment of relapsed lymphoma in dogs: 33 cases (2003–2009). J. Am. Vet. Med. Assoc., v.

239, n. 2, p. 209­215, 2011.

FALCK, K.; GROHN, P.; SORSA, M. Mutagenicity in urine of nurses handling cytostatic drugs. Lancet, v. 1, p. 1250­1251, 1979.

FINK, D.; NEBEL, S.; AEBI, S. et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res., v. 56, n. 21, p. 4881­

4886, 1996.

FLORY, A. B.; RASSNICK, K. M.; AL­SARRAF, R. et al. Combination of CCNU and DTIC chemotherapy for treatment of resistant

lymphoma in dogs. J. Vet. Intern. Med., v. 22, n. 1, p. 164­171, 2008.

FONSECA, S. M.; MACHADO, R. C. L.; PAIVA, D. R. S. et al. Manual de quimioterapia antineoplásica. Rio de Janeiro: Reichmann &

Affonso, 2000.

FRAZIER, D. L.; HAHN, K. A. Commonly used drugs. In: HAHN, K. A.; RICHARDSON, R. C. Cancer chemotherapy: a veterinary

handbook. Malvern: Williams & Wilkins, p. 79­149, 1995.

FRAZIER, D. L.; PRICE, G. S. Use of body surface area to calculate chemotherapeutic drug dose in dogs, II: Limitations imposed by

pharmacokinetic factors. J. Vet. Intern. Med., v. 12, p. 272­278, 1998.

FRIMBERGER, A. E.; COTTER, S. M. Principles of chemotherapy. In: HAHN, K. A.; RICHARDSON, R. C. Cancer chemotherapy: a

veterinary handbook. Malvern: Williams & Wilkins, p. 47­62, 1995.

FRIMBERGER, A. E.; MOORE, A. S.; RASSNICK, K. M. et al. A combination chemotherapy protocol with dose intensification and

autologous bone marrow transplant (VELCAP­HDC) for canine lymphoma. J. Vet. Intern. Med., v. 20, n. 2, p. 355­364, 2006.

FUNDAÇÃO ONCOCENTRO DE SÃO PAULO. Manual de Enfermagem Oncológica. São Paulo: Fosp, 1996.

GANTA, S.; SHARMA, P.; PAXTON, J. W. et al. Pharmacokinetics and pharmacodynamics of chlorambucil delivered in long­circulating

nanoemulsion. J Drug Target., v. 18, n. 2, p. 125­133, 2010.

GARRETT, L. D.; THAMM, D. H.; CHUN, R. et al. Evaluation of a 6­month chemotherapy protocol with no maintenance therapy for

dogs with lymphoma. J. Vet. Intern. Med., v. 16, n. 6, p. 704­709, 2002.

GILSON, S. D.; PAGE, R. L. Princípios de oncologia. In: BICHARD, S. J.; SHERDING, R. G. Manual Saunders: clínica de pequenos

animais. Roca: São Paulo, p. 209­217, 1998.

GOLONI­BERTOLLO, E. M.; TABAJARA, E. H.; MANZATO, A. J. Sister chromatin exchanges and chromosome aberrations in

lymphocytes of nurses handling antineoplastic drugs. Intern. J. Cancer. v. 50, p. 341­344, 1992.

GOODMAN, G. E.; MCLEAN, A.; ALBERTS, D. S. et al. Inhibition of human tumour clonogenicity by chlorambucil and its metabolites.

Brit. J. Cancer, v. 45, n. 4, p. 621, 1982.

GORLICK, R.; GOKER, E.; TRIPPETT, T. et al. Intrinsic and acquired resistance to methotrexate in acute leukemia. N. Engl. J. Med., v.

335, n. 14, p. 1041­1048, 1996.

GORMAN, N. T. Chemotherapy. In: WHITE, R. A. S. Manual of small animal oncology. Shurdington: British Small Animal Veterinary

Association, p. 127­160, 1995.

GRANT, I. A.; RODRIGUEZ, C. O.; KENT, M. S. et al. A phase II clinical trial of vinorelbine in dogs with cutaneous mast cell tumors.

J. Vet. Intern. Med., v. 22, n. 2, p. 388­393, 2008.

GREENBERG, C. B.; BORIA, P. A.; BORGATTI­JEFFREYS, A. et al. Phase II clinical trial of combination chemotherapy with

dexamethasone for lymphoma in dogs. J. Am. Anim. Hosp. Assoc., v. 43, n. 1, p. 27­32, 2007.

GREGORY, R. K.; SMITH, I. E. Vinorelbine–a clinical review. Brit. J. Cancer, v. 82, n. 12, p. 1907, 2000.

GRIESSMAYR, P. C.; PAYNE, S. E.; WINTER, J. E. et al. Dacarbazine as single agent therapy for relapsed lymphoma in dogs. J. Vet.

Intern. Med.. v. 23, n. 6, p. 1227­1231, 2009.

HAHN, K. A. Chromosomal changes associated with cancer. In: MORRISON, W. B. Cancer in dogs and cats: medical and surgical

management. Baltimore: Williams & Wilkins, p. 53­61, 1998.

HAHN, K. A. Vincristine sulfate as single­agent chemotherapy in a dog and a cat with malignant neoplasms. J. Am. Vet. Med. Assoc., v.

197, n. 4, p. 504­506, 1990.

HAHN, K. A.; RICHARDSON, R. C. Cancer chemotherapy: a veterinary handbook. Malvern: Williams & Wilkins, 1995.

HAMILTON, T. A.; COOK, J. R.; BRAUND, K. G. et al. Vincristine induced peripheral neuropathy in a dog. J. Am. Vet. Med. Assoc., v.

198, n. 4, p. 635­638, 1991.

HAMMER, A. S.; COUTO, C. G.; FILPPI, J. et al. Efficacy and toxicity of vac chemotherapy (vincristine, doxorubicin and cyclophospha

mide) in dogs with hemangiosarcoma. J. Vet. Intern. Med., v. 5, n. 3, p. 160­166, 1991.

HELFAND, S. C. Principles and applications of chemotherapy. Vet. Clin. North Am., v. 20, n. 4, p. 987­1013, 1990.

HENRY, C. J. Comparison of chemotherapy safety procedures used in veterinary teaching hospitals and human oncology centers. J. Am.

Vet. Med. Assoc., v. 209, n. 5, p. 974­976, 1996.

HERSH, M. R.; LUDDEN, T. M.; KUHN, J. G. et al. Pharmacokinetics of high dose melphalan. Investigational new drugs, v. 1, n. 4, p.

331­334, 1983.

HOHENHAUS, A. E.; MATUS, R. E. Etoposide (vp­16): retrospective analysis of treatment in 13 dogs with lymphoma. J. Vet. Intern.

Med., v. 4, n. 5, p. 239­241, 1990.

HONG S. H. Intracavitary carboplatina chemotherapy in a malignant mesothelioma dog. J. Vet. Clin., v. 18, n. 2, p. 167­169, 2001.

JARK, P. C.; MACHADO, L. H. A.; LOURENÇO, M. L. G. et al. Uso de inibidores de Cox­2 no tratamento do carcinoma de células de

transição de bexiga em cães – Revisão. Vet. Zootec., v. 18, n. 4, p. 523­530, 2011.

JEFFERY, N.; BREARLEY, M. J. Brain tumours in the dog: treatment of 10 cases and review of recent literature. J. Small Anim. Pract., v.

34, p. 367­372, 1993.

JORDAN, M. A.; WILSON, L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer, v. 4, n. 4, p. 253­265, 2004.

JUNG, D. I.; KIM, H. J.; PARK, C. Long­term chemotherapy with lomustine of intracranial meningioma occurring in a miniature

schnauzer. J. Vet. Med. Sci., v. 68, n. 4, p. 383­386, 2006.

KAYE, M. E.; THAMM, D. H.; WEISHAAR, K. et al. Vinorelbine rescue therapy for dogs with primary urinary bladder carcinoma. Vet.

Comp. Oncol., 2013.

KERBUSCH, T.; DE KRAKER, J.; KEIZER, H. J. et al. Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its

metabolites. Clin. Pharmacok., v. 40, n. 1, p. 41­62, 2001.

KIM, J.; DOERR, M.; KITCHELL, B. E. Exploration of paclitaxel (Taxol) as a treatment for malignant tumors in cats: a descriptive case

series. J. Fel. Med. Surg., v. 17, n. 2, p.186­190, 2015.

KINSELLA, A. R.; SMITH, D.; PICKARD, M. Resistance to chemotherapeutic antimetabolites: a function of salvage pathway

involvement and cellular response to DNA damage. Brit. J. Cancer, v. 75, n. 7, p. 935, 1997.

KISSEBERTH, W. C.; VAIL, D. M.; YAISSLE, J. et al. Phase I clinical evaluation of carboplatina in tumor­bearing cats: a Veterinary

Cooperative Oncology Group Study. J. Vet. Intern. Med., v. 22, p. 83­88, 2008.

KNAPP, D. W.; RICHARDSON, R. C.; CHAN, T. C. K. et al. Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary

bladder. J. Vet. Intern. Med., v. 8, n. 4, p. 273­278, 1994.

KOBAYASHI, H.; MAN, S.; GRAHAM, C. H. et al. Acquired multicellular­mediated resistance to alkylating agents in cancer. Proceed.

Nat. Acad. Sci., v. 90, n. 8, p. 3294­3298, 1993.

KOSAREK, C. E.; KISSEBERTH, W. C.; GALLANT, S. L. Clinical evaluation of gemcitabine in dogs with spontaneously occurring

malignancies. J. Vet. Intern. Med., v. 19, n. 1, p. 81­86, 2005.

LABERKE, S.; ZENKER, I.; HIRSCHBERGER, J. Mesna and furosemide for prevention of cyclophosphamide­induced sterile

haemorrhagic cystitis in dogs–a retrospective study. Vet. Record, v. 174, n. 10, p. 250, 2014.

LANGOVA, V.; MUTSAERS, A. J.; PHILLIPS, B. et al. Treatment of eight dogs with nasal tumours with alternating doses of doxorubicin

and carboplatina in conjunction with oral piroxicam. Austral. Vet. J., v. 82, n. 11, p. 676­680, 2004.

LEACH, T. N.; CHIDRESS, M. O.; GREENE, S. N. et al. Prospective trial of metronomic chlorambucil chemotherapy in dogs with

naturally occurring cancer. Vet. Comp. Oncol., v. 10, n. 2, p. 102­112, 2012.

LEE, F. Y.; WORKMAN, P.; ROBERTS, J. T.; BLEEHEN, N. M. Clinical pharmacokinetics of oral CCNU (lomustine). Cancer

Chemother. Pharmacol., v. 14, n. 2, p. 125­131, 1985.

LEMARIE, S. L.; EDDLESTONE, S. M. Treatment of cutaneous t­cell lymphoma with dacarbazine in a dog. Vet. Dermatol., v. 8, p. 41­

46, 1997.

LIND, M. J.; ARDIET, C. Pharmacokinetics of alkylating agents. Cancer Surveys, v. 17, p. 157­188, 1992.

LIND, M. J.; ROBERTS, H. L.; THATCHER, N. et al. The effect of route of administration and fractionation of dose on the metabolism

of ifosfamide. Cancer Chemother. Pharmacol., v. 26, n. 2, p. 105­111, 1990.

LLOP, J. C.; MATEU, J.; LLOREENT, A. Estravasación de fármacos citostáticos: diagnóstico, evolución y tratamiento. Med. Clin., v.

101, n. 3, p. 105­109, 1993.

LONDON, C. A.; VAIL, D. M. Tumor biology. In: WITHROW, S. J.; MACEWEN, E. G. Small Animal Clinical Oncology. 2. ed. p. 16­30.

Philadelphia: WB Saunders, 1996.

LOUTSIDIS, A.; BELLENIS, I.; ARGIRIOU, M. et al. Tetracycline compared with mechlorethamine in the treatment of malignant

pleural effusions. A randomized trial. Respirat. Med., v. 88, n. 7, p. 523­526, 1994.

MACDONALD, V. S.; THAMM, D. H.; KURZMAN, I. D. et al. Does L­asparaginase influence efficacy or toxicity when added to a

standard CHOP protocol for dogs with lymphoma? J. Vet. Intern. Med., v. 19, n. 5, p. 732­736, 2005.

MACEWEN, E. G.; ROSENTHAL, R. C.; FOX, I. E. et al. Evaluation of l­asparaginase: polyethylene glycol conjugate versus native Lasparaginase combined with chemotherapy: a randomized doubleblind study in canine lymphoma. J. Vet. Intern. Med., v. 6, n. 4, p. 230­

234, 1992.

MACHADO, R. C. L.; ROTEA JR. W.; PAIVA, D. R. S. et al. Cuidados básicos na central de manipulação de quimioterápicos. In:

FONSECA, S. M.; MACHADO, R. C. L.; PAIVA, D. R. S. et al. Manual de Quimioterapia antineoplásica. Rio de Janeiro: Reichmann

& Affonso, p. 90­92, 2000.

MADDISON, J. E.; PEASTON, A. E.; CHURCH, D. B. Treatment of 42 cases of canine lymphosarcoma with combination chemotherapy:

1987­1993. Austral. Vet. J., v. 24, p. 94­101, 1994.

MADEWELL, B. R. Cancer biology. In: HAHN, K. A.; RICHARDSON, R. C. Cancer chemotherapy: a veterinary handbook. Malvern:

Williams & Wilkins, p. 3­22, 1995.

MARCONATO, L.; LORENZO, R. M.; ABRAMO, F.; et al. Adjuvant gemcitabine after surgical removal of aggressive malignant

mammary tumours in dogs. Vet. Comp. Oncol., v. 6, n. 2, p. 90­101, 2008.

MARTINES, J. A.; FLECK, J. A intensidade de dose. In: FLECK, J. Câncer – interação clínica­biológica. Rio de Janeiro: Medsi, 1992.

MASSUNGA, V. M.; JÚNIOR, W. R. Segurança no trabalho e garantia de qualidade. In: FONSECA, S. M.; MACHADO, R. C. L.; PAIVA,

D. R. S. et al. Manual de quimioterapia antineoplásica. Rio de Janeiro: Reichmann & Affonso, p. 71­80, 2000.

MCDIARMID, M. A.; PRESSON, A. C. Controlling occupational exposure to hazardous drugs. Am. J. Health Syst. Pharmacol., v. 53, p.

1669­1685, 1996.

MCENTEE, M. C. Principles of adjunct radiotherapy and chemotherapy. Vet. Clin. North Am. Small Anim. Pract., v. 1, p. 133­148, 1995.

MCENTEE, M. C.; RASSNICK, K. M.; BAILEY, C. E. et al. Phase I and pharmacokinetic evaluation of the combination of orally

administered docetaxel and cyclosporin A in tumor bearing cats. J. Vet. Intern. Med., v. 20, n. 6, p. 1370­1375, 2006.

MOORE, A. S.; FRIMBERGER, A. E.; ETTINGER, S. J. Principles of chemotherapy. In: ETTINGER, S. J. Textbook of veterinary

internal medicine: diseases of the dog and cat. 5. ed. Philadelphia: WB Saunders, p. 484­489, v. 1, 2000.

MORRISON, W. B. Cancer chemotherapy: an annotated history. J. Vet. Intern. Med., v. 24, n. 6, p. 1249­1262, 2010.

MORRISON, W. B. Cancer drug pharmacology and clinical experience. In: Cancer in dogs and cats: medical and surgical management.

Baltimore: Williams & Wilkins, p. 359­377, 1998.

MORRISON, W. B. Chemotherapy. In: Cancer in dogs and cats: medical and surgical management. Baltimore: Williams & Wilkins, p.

351­357, 1998.

MORRISON, W. B. Providing chemotherapy safely. In: Cancer in dogs and cats: medical and surgical management. Baltimore: Williams

& Wilkins, p. 379­85, 1998.

MORRISON, W. R. Chemotherapy safety. In: HAHN, K. A.; RICHARDSON, R. C. Cancer chemotherapy – a veterinary handbook.

Malvern: Williams & Wilkins, p. 63­75, 1995.

MURPHY, S.; HAYES, A.; ADAMS, V. et al. Role of carboplatina in multimodality treatment of canine tonsillar squamous cell

carcinoma: a case series of five dogs. J. Small Anim. Pract., v. 47, n. 4, p. 216­220. 2006.

NORTHRUP, N. C.; GIEGER, T. L.; KOSAREK, C. E. et al. Mechlorethamine, procarbazine and prednisone for the treatment of resistant

lymphoma in dogs. Vet. Comp. Oncol., v. 7, n. 1, p. 38­45, 2009.

OGILVIE, G. K.; MOORE, A. S. Chemotherapy: properties, uses, and patient management. In: Managing the veterinary cancer patient: a

practice manual. Treton: Veterinary Learning Systems, p. 64­85, 1995.

OGILVIE, G. K.; MOORE, A. S. Methods of drug administration. In: Managing the veterinary cancer patient: a practice manual. Treton:

Veterinary Learning Systems, p. 58­63, 1995.

OGILVIE, G. K.; MOORE, A. S. Safe handling of chemotherapeutic agents. In: Managing the veterinary cancer patient: a practice

manual. Treton: Veterinary Learning Systems, p. 53­57, 1995.

OGILVIE, G. K.; OBRADOVICH, J. E.; ELMSLIE, R. E. et al. Efficacy of mitoxantrone against various neoplasm in dogs. J. Am. Vet.

Med. Assoc., v. 198, n. 9, p. 1618­1621, 1991.

PARHAM, P. Manipulação da resposta imune. In: O sistema imune. Artmed: Porto Alegre, p. 327­372, 2001.

PEASTON, A. E.; MADDISON, J. E. Efficacy of doxorubicin as an induction agent for cats with lymphosarcoma. Austral. Vet. J., v. 77, n.

7, p. 442­444, 1999.

POIRIER, V. J.; BURGESS, K. E.; ADAMS, W. M. et al. Toxicity, dosage, and efficacy of vinorelbine (Navelbine) in dogs with

spontaneous neoplasia. J. Vet. Intern. Med., v. 18, n. 4, p. 536­539, 2004.

POLTON, G. A.; BREARLEY, M. J.; POWELL, S. M. et al. Impact of primary tumour stage on survival in dogs with solitary lung

tumours. J. Small Anim. Pract., v. 49, n. 2, p. 66­71, 2008.

POSTORINO, N. C.; SUSANECK, S. J.; WITHROW, S. J. et al. Single agent therapy with adriamycin for canine lymphosarcoma. J. Am.

Anim. Hosp. Assoc., v. 25, n. 2, p. 221­225, 1989.

POWER, L. A. Ashp technical assistance bulletin on handling cytotoxic and hazardous drugs. Am. J. Hosp. Pharm., v. 47, p. 1033­1049,

1990.

PRICE, G. S.; FRAZIER, D. L. Use of body surface area (bsa)­based dosages to calculate chemotherapeutic drug dose in dogs, I: potential

problems with current bsa formulae. J. Vet. Intern. Med., v. 12, p. 267­271, 1998.

RASSNICK, K. M.; MAULDIN, G. E.; AL­SARRAF, R. G. et al. MOPP chemotherapy for treatment of resistant lymphoma in dogs: a

retrospective study of 117 cases (1989–2000). J. Vet. Intern. Med., v. 16, n. 5, p. 576­580, 2002.

RASSNICK, K. M.; MOORE, A. S.; COLLISTER, K. E. et al. Efficacy of combination chemotherapy for treatment of gastrintestinal

lymphoma in dogs. J. Vet. Intern. Med., v. 23, n. 2, p. 317­322, 2009.

RASSNICK, K. M.; MOORE, A. S.; NORTHRUP, N. C. et al. Phase I trial and pharmacokinetic analysis of ifosfamide in cats with

sarcomas. Am. J. Vet. Res., v. 67, n. 3, p. 510­516, 2006.

REID, J. M.; KUFFET, M. J.; MILLER, J. K. et al. Metabolic activation of dacarbazine by human cytochromes P450: the role of

CYP1A1, CYP1A2, and CYP2E1. Clin. Cancer Res., v. 5, n. 8, p. 2192­2197, 1999.

RHOADS, C. P. Nitrogen mustards in the treatment of neoplastic disease: official statement. J. Am. Med. Assoc., v. 131, n. 8, p. 656­658,

1946.

RISBON, R. E.; DE LORIMIER, L. P.; SKORUPSKI, K. et al. Response of canine cutaneous epitheliotropic lymphoma to lomustine

(CCNU): a retrospective study of 46 cases (1999­2004). J. Vet. Intern. Med., v. 20, n. 6, p. 1389­1397, 2006.

ROBERT, J. Multidrug resistance in oncology: diagnostic and therapeutic approaches. Eur. J. Clin. Invest., v. 29, p. 536­545, 1999.

RODASKI, S., DE NARDI, A. B. Quimioterapia antineoplásica em cães e gatos. São Paulo: Medvet Livros, 2007.

ROSENBERG, B. Anticancer activity of cis­dichlorodiammineplatinum (II) and some relevant chemistry. Cancer Treat. Rep., v. 63, n. 9,

p. 1433, 1979.

ROSENTHAL, R. C. Chemotherapy. In: DOUGLAS, S. Textbook of small animal surgery. 2. ed. Philadelphia: WB Saunders, v. 2, p. 2067­

2075, 1993.

ROSENTHAL, R. C. Segredos em oncologia veterinária. São Paulo: Artmed, 2004.

ROSENTHAL, R. C. Veterinary oncology secrets. Baltimore: Williams & Wilkins, 2000.

ROSENTHAL, R. C.; CROW, S. E. Appropriate handling of chemotherapeutic agents in private practice. In: Cancer chemotherapy in

veterinary practice. Denver: American Animal Hospital Association, p. 47­49, 1991.

RUZAFA, I. M.; DOMINGUEZ, P. A.; DERVISIS, N. G. et al. Tolerability of gemcitabine and carboplatina doublet therapy in cats with

carcinomas. J. Vet. Intern. Med., v. 23, n. 3, p. 570­577, 2009.